Please select the option that best describes you:
Topics:
Lung Cancer • Radiation Oncology • Thoracic Malignancies • Medical Oncology • Non-small cell lung cancer
How do you decide between enrolling an oligometastatic NSCLC patient on LU-002 versus treating them with SBRT off trial?
Since the randomized phase II data from Gomez et al presented at ASTRO 2018 showed a survival benefit, is there concern about randomizing patients to a study that has an arm with documented worse survival?
Answer from: Radiation Oncologist at Academic Institution
On behalf of @Puneeth Iyengar, MD, PhD and @Daniel R. Gomez, MDThis question is very important and goes towards the question of equipoise from the perspective of the physician and patient for enrollment on NRG-LU002, accounting for recent data from Gomez et al and Palma et al presented at ASTRO 2018...
Sign in or Register to read more